Funding · Healthcare & Life Sciences

RISA Labs raises $11.1M Series A for oncology AI

By Startup Enthusiast · 14 January 2026

What they do

RISA Labs builds an AI operating system that automates administrative tasks for cancer care

It raised $11.1M in Series A co-led by Cencora Ventures and Optum Ventures

The platform freed up 80% of admin staff time at one partner site and cut denials by 40%

RISA Labs has closed an $11.1M Series A funding round.
The round was co-led by Cencora Ventures and Optum Ventures.
Oncology Ventures, Z21 Ventures, and John Simon (via Ventureforgood) also participated.
The company builds an AI operating system for oncology that automates patient access, benefits verification, and prior authorization.
Its product, BOSS Console, acts as a command control panel for cancer clinics and health systems.
The platform connects to EMR, payer, and benefits systems and uses AI agents to read, reason, and act across them.
Funds will be used to accelerate deployment across US cancer clinics, health systems, specialty pharmacies, and infusion networks.

Healthtech was among the top 10 funded sectors in the Indian startup ecosystem in 2025, with over $700M across 54 deals.
RISA Labs previously raised a $3.5M seed round led by Flipkart co-founder Binny Bansal in April 2025.
The company was founded in June 2024 and is headquartered in Palo Alto, California.

RISA Labs provides an AI operating system for oncology that automates administrative workflows.
Its BOSS Console is a command control panel for mission-critical institutions like cancer clinics and health systems.
The platform connects to EMR, payer, and benefits systems and other systems of record.
AI agents read, reason, and act across systems, adapting in real time to changing forms, rules, and interfaces.
Target customers are cancer clinics, health systems, specialty pharmacies, and infusion networks in the US.
At one partner site, the platform freed up ~80% of administrative staff time, reduced denials by up to 40%, and achieved a 97.8% first-pass approval rate.
Patient authorizations are filed within 24 hours of request, on track to drop below 2 hours from an average 8-day backlog.
In nine months, partner institutions expanded from initial deployment to second and third workflows.

Accelerate deployment across US cancer clinics, health systems, specialty pharmacies, and infusion networks.
Go deeper in oncology, partner with ecosystem leaders, and expand AI-driven workflows across the full continuum of cancer care.
Extend capabilities to specialty pharmacy operations via the BOSS Console.

Cencora Ventures (co-lead) — Corporate venture capital fund of Cencora.
Optum Ventures (co-lead)
Oncology Ventures (participated)
Z21 Ventures (participated)
John Simon (participated) — Co-founder of General Catalyst, investing via Ventureforgood entity.
Binny Bansal (existing) — Flipkart co-founder, led the seed round and continued backing in Series A.

Product: An AI operating system for oncology workflows, centered on its BOSS platform.
Customers: Cancer clinics, health systems, specialty pharmacies, infusion networks and oncology providers.
How it makes money: It sells workflow automation software to healthcare providers in oncology.
What sets it apart: The platform is built for complex oncology rules and uses AI agents to break work into smaller tasks.
Operations: It is targeting deployment across cancer centers in the United States.